Valuation: Ipca Laboratories Limited

Market Cap 448B 4.71B 4.08B 3.8B 3.5B 6.6B 6.68B 44.68B 17.54B 224B 17.69B 17.3B 742B P/E 2027 *
32.1x
P/E 2028 * 26.9x
Enterprise Value 436B 4.58B 3.97B 3.7B 3.4B 6.43B 6.5B 43.5B 17.07B 218B 17.22B 16.84B 722B EV / Sales 2027 *
4.05x
EV / Sales 2028 * 3.53x
Free-Float
54.94%
Yield 2027 *
0.33%
Yield 2028 * 0.35%
1 day+4.15%
1 week-1.34%
Current month+0.98%
1 month-0.78%
3 months+15.36%
6 months+25.50%
Current year+24.39%
1 week 1,682.5
Extreme 1682.5
1,790
1 month 1,682.5
Extreme 1682.5
1,944.9
Current year 1,391.8
Extreme 1391.8
1,944.9
1 year 1,251.6
Extreme 1251.6
1,944.9
3 years 847.3
Extreme 847.3
1,944.9
5 years 669.8
Extreme 669.8
1,944.9
10 years 200
Extreme 200
1,944.9
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 53 11/11/2008
Director/Board Member 70 01/08/1994
Date Insider Type Main position Quantity % Market Cap.
19/12/24 Sell 4,000,000 1.5766%
Change 5-day change 1-year change 3-year change Capi.($)
+4.15%-1.34%+22.30%+94.32% 4.52B
+3.68%-4.13%+51.44%+155.46% 995B
+1.35%-2.71%+51.30%+49.24% 614B
+0.64%-6.49%+24.01%+63.78% 431B
+1.96%+0.83%+42.80%+37.70% 353B
-0.11%-4.07%+30.37%+38.52% 293B
+2.52%-8.36%+7.27%+10.56% 245B
+3.54%+4.76%+35.33%+60.56% 210B
-4.32%-12.94%-3.79%-46.07% 210B
-3.66%-1.58%+16.16%+61.93% 168B
Average +1.00%-5.05%+27.72%+52.60% 352.28B
Weighted average by Cap. +1.49%-5.89%+36.41%+71.95%

Financials

2027 *2028 *
Net sales 108B 1.13B 981M 914M 841M 1.59B 1.61B 10.74B 4.22B 53.88B 4.25B 4.16B 178B 120B 1.26B 1.09B 1.02B 938M 1.77B 1.79B 11.98B 4.7B 60.08B 4.74B 4.64B 199B
Net income 14B 147M 128M 119M 109M 206M 209M 1.4B 548M 7B 553M 541M 23.2B 16.7B 176M 152M 142M 130M 246M 249M 1.67B 654M 8.35B 660M 645M 27.67B
Net Debt -11.82B -124M -108M -100M -92.34M -174M -176M -1.18B -463M -5.92B -467M -457M -19.59B -23.66B -249M -216M -201M -185M -349M -353M -2.36B -927M -11.84B -935M -914M -39.21B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
05/08/26 1,765.00 +4.15% 290,079
04/08/26 ₹1,694.70 -1.79% 222,711
03/08/26 ₹1,725.60 -1.27% 159,711
31/07/26 ₹1,747.80 -0.63% 138,035
30/07/26 ₹1,758.80 -0.88% 140,552
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,765.00INR
Average target price
1,733.50INR
Spread / Average Target
-1.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IPCALAB Stock